Director, Clinical Development
Egetis Therapeutics AB
Director, Clinical Development
Egetis Therapeutics AB
Late-stage rare-disease drug development and commercialization
Late-stage rare-disease drug development and commercialization
Egetis Therapeutics AB develops and commercializes medicines for rare diseases, focusing on late-stage assets. Its lead candidate, Emcitate (tiratricol), treats MCT8 deficiency and has EU approval with a German launch, plus a rolling FDA NDA started in 2025. A second asset, Aladote (calmangafodipir), targets acetaminophen-induced liver injury and holds US/EU orphan designations, with a pivotal trial planned after Emcitate submissions. The company aims to sell directly in Europe and North America while out-licensing in other regions, differentiate itself by concentrating on orphan diseases with clear unmet needs, and pursue regulatory approvals and partnerships to bring therapies to patients.
Explore more opportunities at Egetis Therapeutics AB